DOI: 10.36347/sjams.2020.v08i06.007

Pages: 1420-1423

Objective: In this study my main goal is to evaluate the efficacy of Ivabradine and Nebivolol in the Treatment of Stable Angina Pectoris Patients with Mild Left Ventricular Dysfunction. Methods: This cross-sectional observational study was done in tertiary medical college and hospital from December 2018 to December 2019.A total of 100 consecutive patients were included. The patients were evaluatedin 2 different groups (1,2). In group-1 Nebivolol 5mg/daywas administered to the 50 patients included in GroupA. 50 patients were started onIvabradine 10mg/day and these patients were includedinto group-2. Results: During the study, heart rate decreased (78±6) to (65±5) in Group: 1 and (77± 7) to (70 ± 5) in Group: 2.After 6 months’ treatment LVEFfor the group-1 improved by (48 ± 6.5) to (51 ± 3.2), and forthe group-2 (47± 5.4) to (51 ± 2.3). There is no significant change in EF improvement in both groups.Dose-related sinus bradycardia occurred in (5%) of the nebivolol-using patients included in Group-1, where as in group-2 it was 1%. Conclusion: From my study I can conclude that, Ivabradine can be considered as first choice in patient with tachycardia induced angina as this agent for reducing heart rate as well as chest pain. The hypertensive patient with tachycardia may be treated by Nebivolol. Further study is needed better result.